Human immune response varies by the degree of relative cryptococcal antigen shedding

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Boulware, David R ^a,b   von Hohenberg, Maximilian ^a   Rolfes, Melissa A ^a,b   Bahr, Nathan C ^a   Rhein, Joshua ^a,d   Akampurira, Andrew ^e   Williams, Darlisha A ^a,d   Taseera, Kabanda ^f   Schutz, Charlotte ^g,h,i   McDonald, Tami ^c   Muzoora, Conrad ^f   Meintjes, Graeme ^g,h,i   Meya, David B ^a,d,e   Nielsen, Kirsten ^c   Hullsiek, Katherine Huppler ^b   Musubire, Abdu K ^g   Nabeta, Henry W ^g   Thienemann, Friedrich ^g   Rajasingham, Radha ^g   Scriven, James E ^g   Mwesigy, James ^g   Wagubi, Robert ^g   Kajumbula, Henry ^g   Ndyetukira, Jane Francis ^g   Ahimbisibwe, Cynthia ^g   Kugonza, Florence ^g   Ndyatunga, Liberica ^g   Noeme, Busingye ^g   Memela, Brian ^g   Sigila, Yolisa ^g   Sadiq, Alisat ^g   Magwayi, Monica ^g   Kwizera, Richard ^g   Ninsiima, Emily ^g   Najjuka, Grace ^g   Strain, Anna ^g   Wiesner, Darin ^g   Nanteza, Catherine ^g   Mushagara, Rhina ^g   Hassanally, Leya ^g   Namawejje, Mariam ^g   Ssennono, Mark ^g   Kiragga, Agnes ^g   Butler, Elissa K ^g   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^f MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^g GF Jooste Hospital   (South Africa)

^h Faculty of Health Sciences   (South Africa)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cerebrospinal fluid; Cryptococcal meningitis; Cryptococcus; HIV AIDS; Immune response

Indexed keywords

CRYPTOCOCCAL GLUCURONOXYLOMANNAN ANTIGEN; CYTOKINE; FUNGUS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE CHEMOTACTIC PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC PROCEDURE; FEMALE; GENOTYPE; GLASGOW COMA SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LEUKOCYTE COUNT; LUMINEX MULTIPLEX ASSAY; MAJOR CLINICAL STUDY; MALE; MULTILOCUS SEQUENCE TYPING; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 85000386346     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv194     Document Type: Article

References (25)

1. Durski KN, Kuntz KM, Yasukawa K, et al. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr 2013; 63: e101-8.
2. National Institute for Communicable Diseases. GERMS-SA Annual Report 2012. Available at: http://www.nicd.ac.za/?page=publications&id=155. Accessed 31 May 2013.
3. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
4. Butler EK, Boulware DR, Bohjanen PR, Meya DB. Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One 2012; 7:e51291.
5. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58:736-45.
6. Kabanda T, Siedner MJ, Klausner JD, et al. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis 2014; 58:113-6.
7. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105-13.
8. Kawakami K, Qureshi MH, Zhang T, et al. Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin Exp Immunol 1999; 117:113-22.
9. Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathog 2015; 11:e1004754.
10. Zaragoza O. Multiple disguises for the same party: the concepts of morphogenesis and phenotypic variations in Cryptococcus neoformans. Front Microbiol 2011; 2:181.
11. Zaragoza O, Rodrigues ML, De Jesus M, et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 2009; 68:133-216.
12. Wiesner DL, Specht CA, Lee CK, et al. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog 2015; 11:e1004701.
13. Stenzel W, Muller U, Kohler G, et al. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol 2009; 174:486-96.
14. Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis 2014; 209:74-82.
15. Wiesner DL, Moskalenko O, Corcoran JM, et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio 2012; 3: pii: e00196-12.
16. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487-98.
17. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
18. Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 2014; 20:45-53.
19. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7:e1000384.
20. Liu D, Coloe S, Baird R, Pederson J. Rapid mini-preparation of fungal DNA for PCR. J Clin Microbiol 2000; 38:471.
21. Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 2009; 47:561-70.
22. Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 2006; 172:2223-38.
23. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962-70.
24. Chang CC, Lim A, Omarjee S, et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208:898-906.
25. Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS 2013; 27:2089-99.